Skip to main content

Table 1 Correlation of the CRP/Alb ratio with the baseline and clinicopathological characteristics of patients

From: A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio

Characteristic No. of Patients (%) Pvalue
CRP/Alb ≤ 0.095 CRP/Alb > 0.095  
Gender    0.093
Male 216 (78.3) 125 (85.0)  
Female 60 (21.7) 22 (15.0)  
Age (yr) 58 (24–88) 58 (24–78) 0.388
TNM stage (AJCC, 7th)    <0.001*
I 41 (14.9) 13 (8.8)  
II 131 (47.5) 37 (25.2)  
III 81 (29.3) 61 (41.5)  
IV 23 (8.3) 36 (24.5)  
N stage (AJCC, 7th)    0.015*
N0 154 (59.7) 49 (47.6)  
N1 58 (22.5) 23 (22.3)  
N2 35 (13.6) 25 (24.3)  
N3 11 (4.3) 6 (5.8)  
T stage (AJCC, 7th)    0.003*
T1 32 (12.3) 10 (8.7)  
T2 55 (21.1) 17 (14.8)  
T3 171 (65.5) 75 (65.2)  
T4 3 (1.1) 13 (11.3)  
M stage (AJCC, 7th)    < 0.001*
M0 253 (91.7) 111 (75.5)  
M1 23 (8.3) 36 (24.5)  
Primary tumor size (cm) 3.0 (0.5-11.0) 4.5 (1.0 -10.0) < 0.001*
Tumor location    0.129
Upper 29 (10.5) 7 (4.8)  
Middle 160 (58.0) 92 (62.6)  
Lower 87 (31.5) 48 (32.7)  
Degree of differentiation    0.019*
Poorly or not differentiated 93 (33.7) 66 (44.9)  
Moderately differentiated 173 (62.7) 78 (53.1)  
Well differentiated 10 (3.6) 3 (2.0)  
Surgery    < 0.001*
No 18 (6.5) 42 (28.6)  
Yes 258 (93.5) 105 (71.4)  
Treatment purpose    < 0.001*
Curative treatment 256 (92.8) 102 (69.4)  
Palliative treatment 20 (7.2) 45 (30.6)  
  1. *Significant differences between patients with the CRP/Alb ≤ 0.095 and patients with the CRP/Alb > 0.095.
  2. Abbreviation: TNM tumor-node-metastasis, AJCC American Joint Committee on Cancer, CRP/Alb the C-reactive protein/Albumin ratio.